Fenofibrate as an Adjunct Therapy for Ulcerative Colitis: Targeting Inflammation via SIRT1, NLRP3, and AMPK Pathways: A Randomized Controlled Pilot Study

Drug Des Devel Ther. 2024;18:5239-5253. doi 10.2147/DDDT.S490772

Alarfaj et al. demonstrate fenofibrate significantly improved clinical outcomes, inflammatory biomarkers, and quality of life in patients with mild-to-moderate UC when added to mesalamine therapy.

Through a 6-month double-blind trial involving 70 patients the authors aimed to assess the efficacy of fenofibrate in combination with mesalamine in improving clinical remission and modulating inflammatory pathways, focusing on SIRT1, NLRP3, and AMPK.

Keywords:


Publication thumbnail: Fenofibrate as an Adjunct Therapy for Ulcerative Colitis: Targeting Inflammation via SIRT1, NLRP3, and AMPK Pathways: A Randomized Controlled Pilot Study
LinkedIn